Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Candidatus Saccharimonas aalborgensis

ABSTRACT: Candidatus Saccharimonas aalborgensis Genome sequencing

PROVIDER: PRJNA201542 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Methylomirabilis oxygeniifera (SeqCode)

Project description:Methylomirabilis oxygeniifera (SeqCode) Genome sequencing

| PRJNA348565 | ENA

Methylomirabilales (SeqCode)

Project description:Methylomirabilales (SeqCode) Raw sequence reads

| PRJNA1491664 | ENA

Brachybacterium netajii (SeqCode) strain:DNPG3

Project description:Brachybacterium netajii (SeqCode) strain:DNPG3 Genome sequencing

| PRJNA1380898 | ENA

Stenotrophomonas raiganjensis (SeqCode) strain:RAC2

Project description:Stenotrophomonas raiganjensis (SeqCode) strain:RAC2 Genome sequencing and assembly

| PRJNA1000200 | ENA

Hepatobacter penaei (SeqCode) strain:NHPB

Project description:Hepatobacter penaei (SeqCode) strain:NHPB Genome sequencing and assembly

| PRJNA255047 | ENA

Magnetobacterium casense (SeqCode) strain:MYR-1

Project description:Magnetobacterium casense (SeqCode) strain:MYR-1 Genome sequencing and assembly

| PRJNA236065 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc